ALK receptor tyrosine kinase gene (ALK) fusion is an important driving oncogene in NSCLC, and echinoderm microtubule associated protein like 4 gene (EML4)-ALK fusion is the most prevalent type. With the rapid development and popularity of tumor genomic sequencing, more and more uncommon ALK fusion partners have been discovered, including kinesin family member 5B gene (KIF5B), baculoviral IAP repeat containing 6 gene (BIRC6), and striatin gene (STRN). However, two ALK fusions detected simultaneously in one patient with NSCLC is still rare. Here we present a novel EML4-ALK, B-cell CLL/lymphoma 11A gene (BCL11A)-ALK double-fusion variant in a patient with lung adenocarcinoma who responded well to crizotinib and describe the dynamic change in these two ALK fusions after crizotinib treatment. READ ARTICLE
Journal of Thoracic Oncology DOI:10.1016/j.jtho.2019.01.032
Authors: Bao-Dong Qin, Xiao-Dong Jiao, Ke Liu, Ying Wu, Yuan-Sheng Zang